OncoCyte Corporation (OCX)
NASDAQ: OCX · Real-Time Price · USD
3.060
-0.150 (-4.67%)
Mar 31, 2025, 4:00 PM EDT - Market closed

Company Description

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally.

The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.

It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests.

The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents.

OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

OncoCyte Corporation
OncoCyte logo
Country United States
Founded 2009
Industry Diagnostics & Research
Sector Healthcare
Employees 49
CEO Joshua Riggs

Contact Details

Address:
15 Cushing
Irvine, California 92618
United States
Phone 949 409 7600
Website oncocyte.com

Stock Details

Ticker Symbol OCX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001642380
CUSIP Number 68235C107
ISIN Number US68235C2061
Employer ID 27-1041563
SIC Code 2835

Key Executives

Name Position
Dr. Michael D. West Ph.D. Scientific Advisor, Co-Chief Executive Officer of Biotime,Inc. and President of Biotime,Inc.
Joshua Riggs President, Chief Executive Officer and Director
Yuh-Min Chiang Ph.D. Chief Technology Officer
Peter Hong Vice President, General Counsel and Secretary
Sandra O'Donald Senior Vice President of Business Operations
Dr. Paul R. Billings FACP, M.D. Consulting Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 28, 2025 S-1 General form for registration of securities under the Securities Act of 1933
Mar 24, 2025 10-K Annual Report
Mar 24, 2025 8-K Current Report
Mar 10, 2025 8-K Current Report
Mar 4, 2025 SCHEDULE 13G/A Filing
Feb 24, 2025 D Notice of Exempt Offering of Securities
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 10, 2025 SCHEDULE 13D/A Filing
Feb 10, 2025 8-K Current Report
Feb 10, 2025 424B5 Filing